COUR Pharmaceuticals’ emerging platform reprograms the immune system to address the root causes of autoimmune diseases.

Argenx had cash, cash equivalents, and other short-term investments totaling $3.4 billion as of the end of 2024, making it well-positioned to continue funding its pipeline and commercialization ...

Anti-acetylcholine receptor antibody (AChR-Ab) titers and the AChR-Ab rates of change correlated with myasthenia gravis disease severity scores in a recent study. Using anti-acetylcholine receptor ...

Opens in a new tab or window Recently approved treatments for generalized myasthenia gravis (gMG), including ... given the heterogeneity of the disease, individual comorbidities, and the numerous ...

Nipocalimab is actually being developed across 3 segments of autoantibody-driven diseases. So we've talked about myasthenia gravis, which is a sort of directly autoantibody-driven rare disease.

The company is running three Phase II programs right now in primary biliary cholangitis, diabetes and myasthenia gravis. COUR will be facing some major Big Pharma peers in myasthenia; Argenx’s Vyvgart ...

3,4 However, myasthenia gravis occurs in only a fraction of 1 per cent of the thyrotoxic population. 5 The two diseases often do not begin simultaneously; either one may precede the other by many ...

gMG is an autoimmune disease where the immune system mistakenly ... the researchers measured the effect of Vyvgart using a test called the Myasthenia Gravis-Specific Activities of Daily Living ...